Wird geladen...
Imatinib-Resistant CML Cells Have Low ENT Activity but Maintain Sensitivity to Gemcitabine
Philadelphia chromosome-positive chronic myelogenus leukemia (CML) is widely treated with imatinib mesylate (imatinib), a potent inhibitor of the Bcr-Abl tyrosine kinase. However, resistance to this compound remains a concern. Current treatment approaches include combinations of imatinib with nucleo...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2008
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2702138/ https://ncbi.nlm.nih.gov/pubmed/18600540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15257770802145892 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|